Title:
COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
Document Type and Number:
WIPO Patent Application WO/2022/037684
Kind Code:
A1
Abstract:
Methods for treating systemic lupus erythematosus using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with lupus nephritis. In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced excretion of protein in the urine of the patient, reduced serum anti-dsDNA autoantibody levels in the patient, reduced skin lesion severity in the patient, reduced lymphadenopathy severity in the patient, reduced glomerulonephritis severity in the patient, reduced vasculitis severity in the patient, reduced lymphocyte cell counts in a peripheral blood mononuclear cell (PMBC) panel taken from the patient, reduced lymphocyte cell counts in the spleen of the patient, and reduced lymphocyte infiltration of the kidneys of the patient.
More Like This:
| WO/2024/081718 | CGRP RECEPTOR ANTAGONIST FOR THE TREATMENT OF MIGRAINE |
| JP2013064015 | AZAINDOLE USEFUL AS INHIBITOR OF PROTEIN KINASE |
| WO/2021/124222 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS |
Inventors:
ZHAI YIFAN (CN)
YANG DAJUN (CN)
FANG DONG (CN)
ZHU SAIJIE (CN)
YANG DAJUN (CN)
FANG DONG (CN)
ZHU SAIJIE (CN)
Application Number:
PCT/CN2021/113832
Publication Date:
February 24, 2022
Filing Date:
August 20, 2021
Export Citation:
Assignee:
ASCENTAGE PHARMA SUZHOU CO LTD (CN)
ASCENTAGE PHARMA GROUP CORP LTD (CN)
ASCENTAGE PHARMA GROUP CORP LTD (CN)
International Classes:
A61K31/437; A61P37/00; A61P37/02; C07D471/04
Domestic Patent References:
| WO2020228695A1 | 2020-11-19 | |||
| WO2021000899A1 | 2021-01-07 | |||
| WO2021110097A1 | 2021-06-10 | |||
| WO2018027097A1 | 2018-02-08 | |||
| WO2020024834A1 | 2020-02-06 | |||
| WO2020024916A1 | 2020-02-06 | |||
| WO2020103921A1 | 2020-05-28 | |||
| WO2012071374A1 | 2012-05-31 | |||
| WO2014158528A1 | 2014-10-02 |
Other References:
NADER AHMED, MINOCHA MUKUL, OTHMAN AHMED: "Exposure-response analyses of the effects of venetoclax, a selective BCL-2 inhibitor, on B-lymphocyte and total lymphocyte counts in women with systemic lupus erythematosus", CLINICAL PHARMACOKINETICS, vol. 59, no. 3, 21 September 2019 (2019-09-21), NZ , pages 335 - 347, XP009534383, ISSN: 0312-5963, DOI: 10.1007/s40262-019-00818-5
MINOCHA MUKUL, ZENG JIEWEI, MEDEMA JEROEN, OTHMAN AHMED: "Pharmacokinetics of the B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax in female subjects with systemic lupus erythematosus", CLINICAL PHARMACOKINETICS, vol. 57, no. 9, 15 January 2018 (2018-01-15), NZ , pages 1185 - 1198, XP009534384, ISSN: 0312-5963, DOI: 10.1007/s40262-017-0625-2
MINOCHA MUKUL, ZENG JIEWEI, MEDEMA JEROEN, OTHMAN AHMED: "Pharmacokinetics of the B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax in female subjects with systemic lupus erythematosus", CLINICAL PHARMACOKINETICS, vol. 57, no. 9, 15 January 2018 (2018-01-15), NZ , pages 1185 - 1198, XP009534384, ISSN: 0312-5963, DOI: 10.1007/s40262-017-0625-2
Attorney, Agent or Firm:
KING & WOOD MALLESONS (CN)
Download PDF:
Previous Patent: COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
Next Patent: VEHICLE MEASURING DEVICE
Next Patent: VEHICLE MEASURING DEVICE